Tourmaline Bio (TRML) AI Stock Analysis

• Market Cap: $405.36M
• Dividend Yield: N/A
• Average Volume (3M): 352.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: N/A
• EPS Growth: 74.59%
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.89
• Shares Outstanding: 25,688,478
• 10 Day Avg. Volume: 316,491
• 30 Day Avg. Volume: 352,142
• PEG Ratio: 0.42
• Price to Book (P/B): 1.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $55.20
• Price Target Upside: 255.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

Tourmaline Bio's overall stock score reflects substantial financial and profitability challenges. While the technical indicators suggest some positive momentum, the negative P/E ratio and lack of dividend yield indicate valuation concerns. The strong equity position is a positive, but is overshadowed by the company's significant cash flow issues and lack of revenue growth.

Positive Factors

Efficacy and Dosing

Pacibekitug has the potential to be a best-in-class IL-6 inhibitor in ASCVD, with Tourmaline having multiple ways to win given its characteristics.

Market Opportunity

The asset could still represent a meaningful commercial opportunity given the size of the ASCVD market and the scarcity of IL-6 inhibitors in development for the disease.

Negative Factors

Competition

TRML expects pacibekitug to show hsCRP reductions that are comparable to competing IL-6 agents, ideally with less frequent dosing.

Data Importance

The totality of the data – balance between efficacy and safety – will be more important than superior hs-CRP reduction compared to ziltivekimab’s Phase 2 RESCUE trial.

Tourmaline Bio Business Overview & Revenue Model

Company Description

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

How the Company Makes Money

Tourmaline Bio makes money primarily through the development and commercialization of its proprietary biologic therapies. The company generates revenue by licensing its technology and products to larger pharmaceutical firms, entering into strategic partnerships that provide upfront payments, milestone payments, and royalties on future sales. Additionally, Tourmaline Bio might receive funding from government grants and research collaborations that support its drug development efforts. As its pipeline matures, the company also aims to benefit from direct sales of its approved therapies.

Tourmaline Bio Financial Statement Overview

Summary

Tourmaline Bio faces significant financial challenges, particularly in profitability and cash flow management. Despite maintaining a strong equity position with low leverage, ongoing losses, negative cash flow, and minimal revenue generation present substantial hurdles.

Income Statement

Tourmaline Bio's income statement reflects a challenging financial environment. The company has a gross profit margin of 25% for the TTM, but significant negative EBIT and EBITDA margins indicate operating difficulties. The net profit margin is also negative, at -207,172.5% for TTM. The absence of revenue in previous periods and a minimal revenue in the current period highlight growth challenges.

Balance Sheet

The balance sheet shows a relatively strong equity position with a debt-to-equity ratio of 0.0007 for TTM, indicating low leverage. However, the return on equity is negative due to ongoing losses, and the equity ratio is robust at 97.34% for TTM. These metrics suggest financial stability but highlight profitability issues.

Cash Flow

Tourmaline Bio's cash flow analysis reveals significant challenges, with a negative operating cash flow to net income ratio and free cash flow to net income ratio for TTM. The free cash flow growth rate is also negative, indicating cash generation issues. These factors point to liquidity concerns and operational inefficiencies.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
40.00K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
10.00K	0.00	-33.00K	-6.00K	-623.00K	-447.00K
	EBIT
-98.45M	-89.73M	-45.41M	-19.70M	-904.00	-22.68M
	EBITDA
-98.47M	-89.73M	-45.38M	-19.70M	-46.88M	-22.24M
	Net Income Common Stockholders
-82.87M	-73.21M	-42.12M	-19.70M	-904.00	-22.71M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
249.31M	258.30M	202.95M	8.26M	150.00K	149.49M
	Total Assets
287.50M	309.00M	210.29M	9.10M	150.00K	152.78M
	Total Debt
196.00K	244.00K	415.00K	504.00K	150.00K	0.00
	Net Debt
-35.13M	-30.26M	-140.31M	-7.75M	0.00	-17.59M
	Total Liabilities
7.63M	8.95M	5.25M	28.83M	376.00K	4.77M
	Stockholders Equity
279.86M	300.05M	205.04M	-19.73M	-226.00K	148.00M
Cash Flow		Free Cash Flow
-84.04M	-77.27M	-28.14M	-11.53M	-42.42M	-20.50M
	Operating Cash Flow
-84.02M	-77.26M	-28.08M	-6.46M	-39.99M	-19.21M
	Investing Cash Flow
20.50M	-194.31M	3.84M	-5.07M	-96.39M	-133.30M
	Financing Cash Flow
558.00K	161.35M	156.72M	19.85M	137.40M	131.12M

Tourmaline Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRML, the sentiment is Negative. The current price of 15.54 is below the 20-day moving average (MA) of 16.20, below the 50-day MA of 15.55, and below the 200-day MA of 19.18, indicating a bearish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 49.10 is Neutral, neither overbought nor oversold. The STOCH value of 41.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRML.

Tourmaline Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TALK	61 Neutral	$515.33M	183.83	2.52%	―	25.02%	―
KROS	53 Neutral	$558.06M	―	0.71%	―	91657.69%	97.21%
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%
ZVRA	50 Neutral	$423.77M	―	-207.84%	―	-14.02%	-72.44%
TRML	45 Neutral	$405.36M	―	-26.14%	―	―	74.59%
ORIC	43 Neutral	$384.59M	―	-48.45%	―	―	7.15%
ERAS	34 Underperform	$393.77M	―	-43.68%	―	―	10.38%

Tourmaline Bio Corporate Events

Tourmaline Bio Updates on Clinical Progress and Outlook

Tourmaline Bio has released an updated corporate presentation detailing its progress and future plans, including significant clinical trial milestones for its lead product, pacibekitug. The company is well-financed, with cash expected to fund operations into 2027, positioning it to achieve key milestones that could enhance its market position and provide value to stakeholders.

Tourmaline Bio Unveils Clinical Progress and New Indication

Tourmaline Bio announced key updates at its Investor Day, highlighting progress in its clinical trials and strategic priorities. The company reported over-enrollment in its Phase 2 TRANQUILITY trial and introduced a new indication for pacibekitug, abdominal aortic aneurysm, while planning further developments contingent on trial outcomes, positioning itself for potential expansion in cardiovascular inflammation treatment.